Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RCC
MCID: RNL114
MIFTS: 78

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

About this section

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 56 29 6
Renal Cell Carcinoma 56 12 74 52 58 73 36 15 17 71
Adenocarcinoma of Kidney 56 12 52 73
Rcc 56 12 58 73
Hypernephroma 56 12 73
Hereditary Clear Cell Renal Cell Carcinoma 58 71
Renal Carcinoma, Chromophobe, Somatic 56 13
Nonpapillary Renal Cell Carcinoma 12 15
Clear Cell Renal Carcinoma 73 17
Renal Cell Adenocarcinoma 52 17
Carcinoma, Renal Cell 43 39
Hereditary Clear Cell Renal Cell Adenocarcinoma 58
Renal Cell Carcinoma, Clear Cell, Somatic 56
Conventional Renal Cell Carcinoma 71
Carcinoma, Renal Cell, Nonpapillary 39
Renal Cell Carcinoma Non-Papillary 73
Conventional Renal Cell Carcinoma 73
Renal Cell Carcinoma, Somatic 56
Common Renal Cell Carcinoma 73
Carcinoma Renal Cell 54
Renal Cell Cancer 15
Ccrcc 73
Crcc 73

Characteristics:

Orphanet epidemiological data:

58
renal cell carcinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;
hereditary clear cell renal cell carcinoma
Age of onset: Adult;

HPO:

31
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:0050387 DOID:4450
OMIM 56 144700
KEGG 36 H00021
MeSH 43 D002292
NCIt 49 C9385
SNOMED-CT 67 41607009 702391001
MESH via Orphanet 44 D002292
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0007134
UMLS 71 C0007134 C0279702 C1333985
Sources

Summaries for Renal Cell Carcinoma, Nonpapillary

About this section
OMIM : 56 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to hereditary renal cell carcinoma and kidney cancer, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is FLCN (Folliculin), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Fentanyl and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and endothelial, and related phenotypes are renal cell carcinoma and Decreased sensitivity to paclitaxel

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

KEGG : 36 Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.

UniProtKB/Swiss-Prot : 73 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 74 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Sources

Related Diseases for Renal Cell Carcinoma, Nonpapillary

About this section

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1281)
# Related Disease Score Top Affiliating Genes
1 hereditary renal cell carcinoma 35.6 RNF139 MET FLCN FHIT
2 kidney cancer 35.5 VHL TP53 SETD2 RNF139 PTEN PIK3CA
3 clear cell renal cell carcinoma 35.2 VHL TP53 SETD2 RNF139 PTEN OGG1
4 chromophobe renal cell carcinoma 35.1 VHL SETD2 RNF139 OGG1 HNF1B HNF1A
5 clear cell papillary renal cell carcinoma 35.0 VHL HNF1A
6 renal cell carcinoma, papillary, 1 34.8 VHL TP53 SETD2 PTEN PIK3CA NRAS
7 cowden syndrome 1 34.0 TP53 PTEN PIK3CA MTOR
8 birt-hogg-dube syndrome 33.8 PTEN MTOR FLCN
9 lung cancer susceptibility 3 33.1 TP53 SETD2 PTEN PIK3CA OGG1 NRAS
10 neuroblastoma 32.8 TP53 PTEN PIK3CA NRAS MTOR MET
11 hepatocellular carcinoma 32.7 TP53 PTEN PIK3CA NRAS MTOR MIR200C
12 pancreatic cancer 32.7 TP53 PTEN PIK3CA MTOR MIR200C MIR141
13 lung cancer 32.6 VHL TP53 SETD2 PTEN PIK3CA OGG1
14 esophageal cancer 32.5 TP53 PTEN PIK3CA OGG1 MTOR MIR200C
15 prostate cancer 32.5 TP53 SETD2 PTEN PIK3CA MTOR MIR200C
16 lymphoma, non-hodgkin, familial 32.4 TP53 PTEN PIK3CA NRAS MTOR ATM
17 leukemia, acute myeloid 32.3 TP53 SETD2 PTEN PIK3CA NRAS MTOR
18 ovarian clear cell carcinoma 32.2 TP53 PTEN PIK3CA MTOR MET HNF1B
19 gastric cancer 32.2 TP53 PTEN PIK3CA OGG1 NRAS MTOR
20 cholangiocarcinoma 32.2 TP53 PIK3CA OGG1 MTOR MIR141 MET
21 tuberous sclerosis 32.1 VHL TP53 PTEN PIK3CA MTOR FLCN
22 thyroid tumor 32.1 TP53 PTEN PIK3CA NRAS
23 melanoma 32.1 TP53 PTEN PIK3CA NRAS MTOR MIR200C
24 glioblastoma multiforme 32.1 TP53 PTEN PIK3CA NRAS MTOR MET
25 endometrial cancer 32.1 TP53 PTEN PIK3CA NRAS MTOR MIR200C
26 nasopharyngeal carcinoma 32.0 TP53 PTEN PIK3CA NRAS MTOR MIR141
27 colorectal cancer 32.0 TP53 SETD2 PTEN PIK3CA OGG1 NRAS
28 squamous cell carcinoma, head and neck 32.0 TP53 SETD2 PTEN PIK3CA OGG1 MIR141
29 suppression of tumorigenicity 12 32.0 TP53 PTEN PIK3CA MTOR ATM
30 adrenocortical carcinoma, hereditary 32.0 TP53 PIK3CA NRAS
31 pancreatic adenocarcinoma 31.9 TP53 PTEN PIK3CA MET ATM
32 collecting duct carcinoma 31.9 VHL SETD2 FLCN FHIT
33 lung squamous cell carcinoma 31.9 TP53 PTEN PIK3CA OGG1 MTOR MET
34 myeloma, multiple 31.9 TP53 PTEN NRAS MTOR MET ATM
35 melanoma, uveal 31.9 TP53 PTEN PIK3CA NRAS MET
36 chordoma 31.8 TP53 PTEN MTOR MET
37 leukemia, chronic lymphocytic 31.8 TP53 PTEN PIK3CA NRAS MIR141 ATM
38 cystic kidney disease 31.8 VHL MTOR HNF1B FLCN
39 gastric adenocarcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR MET
40 cowden syndrome 31.8 TP53 PTEN PIK3CA MTOR FLCN ATM
41 glioma 31.8 TP53 PTEN PIK3CA MET ATM
42 mantle cell lymphoma 31.8 TP53 PTEN PIK3CA MTOR ATM
43 bladder urothelial carcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR FHIT
44 bladder cancer 31.7 TP53 PTEN PIK3CA OGG1 NRAS MIR141
45 thyroid gland cancer 31.7 TP53 PTEN PIK3CA NRAS MET
46 adenoid cystic carcinoma 31.7 TP53 PTEN PIK3CA MTOR ATM
47 ovarian clear cell adenocarcinoma 31.7 TP53 PIK3CA MTOR MET HNF1B
48 thyroid gland anaplastic carcinoma 31.6 TP53 PTEN PIK3CA NRAS MET
49 medulloblastoma 31.6 TP53 PTEN PIK3CA NRAS MTOR MET
50 lynch syndrome 31.6 TP53 PTEN PIK3CA OGG1 ATM

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary
Sources

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

About this section

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

31
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584

Clinical features from OMIM:

144700

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

GenomeRNAi Phenotypes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.32 PTEN

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Nonpapillary:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 ATM FLCN HNF1A HNF1B MET MTOR
2 growth/size/body region MP:0005378 10.25 ATM FLCN HNF1A HNF1B HSPBAP1 MET
3 homeostasis/metabolism MP:0005376 10.25 ATM FHIT FLCN HNF1A HNF1B MET
4 embryo MP:0005380 10.22 ATM FLCN HNF1B MET MTOR NRAS
5 cardiovascular system MP:0005385 10.21 ATM FLCN MET MTOR NRAS PIK3CA
6 immune system MP:0005387 10.21 ATM FHIT FLCN HNF1B MET MTOR
7 endocrine/exocrine gland MP:0005379 10.16 ATM HNF1A HNF1B MET MTOR NRAS
8 adipose tissue MP:0005375 10.13 ATM HNF1A HSPBAP1 MTOR PIK3CA PTEN
9 mortality/aging MP:0010768 10.1 ATM FHIT FLCN HNF1A HNF1B MET
10 liver/biliary system MP:0005370 9.97 HNF1A HNF1B MET NRAS OGG1 PTEN
11 muscle MP:0005369 9.76 HNF1A HNF1B MET MTOR PIK3CA PTEN
12 neoplasm MP:0002006 9.7 ATM FHIT FLCN MET NRAS OGG1
13 renal/urinary system MP:0005367 9.23 FLCN HNF1A HNF1B MET MTOR PTEN
Sources

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

About this section

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 456)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Caffeine Approved Phase 4 58-08-2 2519
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
11
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
12 Neurotransmitter Agents Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Adrenergic Agents Phase 4
15 Anesthetics Phase 4
16 Adrenergic Agonists Phase 4
17 Anesthetics, General Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Narcotics Phase 4
20 Analgesics, Opioid Phase 4
21 Hypnotics and Sedatives Phase 4
22 Anesthetics, Local Phase 4
23 Central Nervous System Stimulants Phase 4
24 Phosphodiesterase Inhibitors Phase 4
25 Psychotropic Drugs Phase 4
26 Anesthetics, Intravenous Phase 4
27 GABA Modulators Phase 4
28 Cholinergic Agents Phase 4
29 Anesthetics, Inhalation Phase 4
30 Adrenergic beta-Agonists Phase 4
31 Respiratory System Agents Phase 4
32 Vasoconstrictor Agents Phase 4
33 Anti-Asthmatic Agents Phase 4
34 Mydriatics Phase 4
35 Bronchodilator Agents Phase 4
36 Sympathomimetics Phase 4
37 Dopamine Agents Phase 4
38 Nicotinic Agonists Phase 4
39 Antidepressive Agents Phase 4
40 Protein Kinase Inhibitors Phase 4
41 Liver Extracts Phase 4
42
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4 5360545
43
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
44
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
45
Ethanol Approved Phase 3 64-17-5 702
46
Promethazine Approved, Investigational Phase 3 60-87-7 4927
47
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
48
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
49
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
50
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515

Interventional clinical trials:

(show top 50) (show all 1665)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
3 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
4 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
5 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
6 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
8 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
10 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
11 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
12 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
13 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
14 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 ICE-SECRET PROSENSEâ„¢ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
17 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
18 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
19 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
20 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
21 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
22 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
23 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
24 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
25 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
26 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
27 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Unknown status NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
28 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
29 Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib Unknown status NCT00930033 Phase 3
30 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
31 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
32 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
33 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
34 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
35 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
36 Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC). Completed NCT00502034 Phase 3 Interferon Alfa-2a;Interleukin-2
37 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
38 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
39 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
40 A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer. Completed NCT00073307 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
41 An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
42 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib;Sorafenib
43 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3
44 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU
45 AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy Completed NCT00005995 Phase 3 shark cartilage extract AE-941
46 Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma Completed NCT00018941 Phase 3
47 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
48 A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
49 AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL Completed NCT00678392 Phase 3 Axitinib (AG-013736);Sorafenib
50 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: carcinoma, renal cell

Sources

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

About this section

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 FLCN HNF1A HNF1B OGG1 RNF139 VHL
Sources

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

About this section

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

40
Kidney, Lung, Endothelial, Bone, Brain, T Cells, Thyroid
Sources

Publications for Renal Cell Carcinoma, Nonpapillary

About this section

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 30756)
# Title Authors PMID Year
1
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 61 6 56
25911086 2015
2
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 6 56 54
15649945 2005
3
Integrated molecular analysis of clear-cell renal cell carcinoma. 56 61
23797736 2013
4
Comprehensive molecular characterization of clear cell renal cell carcinoma. 61 56
23792563 2013
5
BAP1 loss defines a new class of renal cell carcinoma. 61 56
22683710 2012
6
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 54 61 46
18925646 2008
7
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. 61 56
18260086 2008
8
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. 61 56
17539022 2007
9
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. 61 56
17311301 2007
10
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 56 61
16798883 2006
11
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 61 56
16814207 2006
12
Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. 56 61
15016767 2004
13
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 56 54
12837690 2003
14
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. 56 61
12694227 2003
15
Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 56 54
11284032 2001
16
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. 61 56
10807693 2000
17
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. 61 56
10232606 1999
18
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. 61 56
9721855 1998
19
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. 61 56
9689122 1998
20
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. 61 56
9585616 1998
21
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. 61 56
9461085 1998
22
The Heidelberg classification of renal cell tumours. 61 56
9390023 1997
23
Renal-cell carcinoma. 61 56
8778606 1996
24
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. 56 61
8159756 1994
25
Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 56 61
1433648 1992
26
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. 61 56
1348014 1992
27
Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 61 56
1553556 1992
28
Molecular and cellular characterization of human renal cell carcinoma cell lines. 56 61
1345811 1992
29
The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. 61 56
1685475 1991
30
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. 56 61
1671000 1991
31
Familial renal cell carcinoma: hereditary or coincidental? 56 61
2398557 1990
32
Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. 56 61
1969617 1990
33
A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. 56 61
2914707 1989
34
Do human renal cell carcinomas arise by a double-loss mechanism? 56 61
3203309 1988
35
Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. 61 56
3417313 1988
36
Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. 61 56
3395987 1988
37
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. 61 56
2835149 1988
38
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. 61 56
2894030 1988
39
Loss of der(3) in renal carcinoma cells of a patient with constitutional t(3;12). 56 61
3422215 1988
40
Specific chromosome aberration in human renal cell carcinoma. 56 61
3610386 1987
41
Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. 56 61
3594418 1987
42
Deletion 3p: the only chromosome loss in a primary renal cell carcinoma. 61 56
3567881 1987
43
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. 56 61
2885753 1987
44
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. 56 61
3467112 1986
45
Rearrangement of chromosome 3 in renal cell carcinoma. 56 61
3943052 1986
46
Specific chromosome anomalies and predisposition to human breast, renal cell, and colorectal carcinoma. 61 56
3940177 1986
47
Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. 61 56
6704944 1984
48
Two human c-onc genes are located on the long arm of chromosome 8. 56 61
6961456 1982
49
Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. 61 56
7112106 1982
50
Neuroblastoma, pheochromocytoma, and renal cell carcinoma. Occurrence in a single patient. 61 56
490809 1979
Sources

Variations for Renal Cell Carcinoma, Nonpapillary

About this section

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6 (show top 50) (show all 1000) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CTNNB1 NM_001904.4(CTNNB1):c.1374A>C (p.Glu458Asp)SNV other 438755 rs1553631848 3:41275208-41275208 3:41233717-41233717
2 HNF1A NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys)SNV Pathogenic 447503 rs1555212014 12:121432067-121432067 12:120994264-120994264
3 VHL NM_001354723.2(VHL):c.*84_*90deldeletion Pathogenic 694389 3:10191534-10191540 3:10149850-10149856
4 MTOR NM_004958.4(MTOR):c.3026G>A (p.Arg1009Gln)SNV Pathogenic 801436 1:11288729-11288729 1:11228672-11228672
5 VHL NM_000551.3(VHL):c.548C>A (p.Ser183Ter)SNV Pathogenic 2215 rs5030823 3:10191555-10191555 3:10149871-10149871
6 VHL NM_000551.4(VHL):c.481C>T (p.Arg161Ter)SNV Pathogenic 2217 rs5030818 3:10191488-10191488 3:10149804-10149804
7 VHL NM_000551.3(VHL):c.499C>T (p.Arg167Trp)SNV Pathogenic 2218 rs5030820 3:10191506-10191506 3:10149822-10149822
8 ATM ATM, IVS61DS, 2-BP INS, +2TAinsertion Pathogenic 3037
9 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
10 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
11 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
12 MET NM_001127500.3(MET):c.3446T>C (p.Met1149Thr)SNV Pathogenic 13881 rs121913668 7:116418881-116418881 7:116778827-116778827
13 MET NM_001127500.3(MET):c.3616G>T (p.Val1206Leu)SNV Pathogenic 13882 rs121913669 7:116422081-116422081 7:116782027-116782027
14 MET NM_001127500.3(MET):c.3637C>G (p.Leu1213Val)SNV Pathogenic 13886 rs121913673 7:116422102-116422102 7:116782048-116782048
15 MET NM_001127500.3(MET):c.3335A>G (p.His1112Arg)SNV Pathogenic 13887 rs121913243 7:116417464-116417464 7:116777410-116777410
16 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
17 HNF1A NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)SNV Pathogenic 14928 rs137853236 12:121435307-121435307 12:120997504-120997504
18 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
19 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
20 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
21 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
22 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
23 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
24 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
25 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
26 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
27 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
28 MET NM_001127500.3(MET):c.3328G>A (p.Val1110Ile)SNV Pathogenic 186141 rs786202724 7:116417457-116417457 7:116777403-116777403
29 MTOR NM_004958.4(MTOR):c.4448G>T (p.Cys1483Phe)SNV Pathogenic 190121 rs786205165 1:11217230-11217230 1:11157173-11157173
30 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
31 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter)SNV Pathogenic 253251 rs879255678 17:17118502-17118502 17:17215188-17215188
32 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
33 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
34 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
35 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
36 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
37 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
38 TP53 NM_001126112.2(TP53):c.374C>G (p.Thr125Arg)SNV Pathogenic/Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
39 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro)SNV Pathogenic/Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
40 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr)SNV Pathogenic/Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
41 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
42 MTOR NM_004958.4(MTOR):c.4447T>C (p.Cys1483Arg)SNV Pathogenic/Likely pathogenic 374796 rs1057519914 1:11217231-11217231 1:11157174-11157174
43 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
44 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
45 TP53 NM_001126112.2(TP53):c.824G>A (p.Cys275Tyr)SNV Pathogenic/Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
46 FLCN NM_144997.7(FLCN):c.779+1G>TSNV Pathogenic/Likely pathogenic 231274 rs758175953 17:17125814-17125814 17:17222500-17222500
47 TP53 NM_001126112.2(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
48 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
49 TP53 NM_001126112.2(TP53):c.527G>A (p.Cys176Tyr)SNV Pathogenic/Likely pathogenic 186451 rs786202962 17:7578403-7578403 17:7675085-7675085
50 TP53 NM_001126112.2(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

73
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9 (show top 50) (show all 7561)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 15
2 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 15
3 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
4 COSM94790253 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 15
5 COSM87583829 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 9:107003322-107003322 15
6 COSM137390699 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 15
7 COSM151995781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 15
8 COSM85326448 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 15
9 COSM105902090 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 15
10 COSM149301355 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.4509G>T p.Q1503H 16:72798173-72798173 15
11 COSM149268221 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 15
12 COSM149269629 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 15
13 COSM149266502 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 15
14 COSM89411866 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 6:151366135-151366135 15
15 COSM152022098 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 15
16 COSM143036610 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
17 COSM87436198 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1299C>A p.F433L 13:20809842-20809842 15
18 COSM101982001 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 15
19 COSM136040220 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 20:31997126-31997126 15
20 COSM94289984 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 15
21 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 15
22 COSM96278984 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 15
23 COSM91370315 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1432+1G>C p.? 11:32391971-32391971 15
24 COSM91379363 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.536C>A p.P179H 11:32434810-32434810 15
25 COSM89581411 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 15
26 COSM101580971 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 15
27 COSM101322652 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 15
28 COSM101325565 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 15
29 COSM96870566 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 15
30 COSM94748869 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860= 8:99274262-99274262 15
31 COSM88289499 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>T p.V130F 3:10146561-10146561 15
32 COSM88290593 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>A p.? 3:10149786-10149786 15
33 COSM88305492 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.291C>A p.P97= 3:10142138-10142138 15
34 COSM88291276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 15
35 COSM88303076 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.293A>T p.Y98F 3:10142140-10142140 15
36 COSM88289037 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.254T>C p.L85P 3:10142101-10142101 15
37 COSM88289748 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 3:10149848-10149848 15
38 COSM88292344 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 3:10142133-10142133 15
39 COSM88292485 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>T p.P81S 3:10142088-10142088 15
40 COSM88307936 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.244C>T p.R82C 3:10142091-10142091 15
41 COSM88289384 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.263G>T p.W88L 3:10142110-10142110 15
42 COSM88290429 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.350G>T p.W117L 3:10146523-10146523 15
43 COSM88294468 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.473T>G p.L158R 3:10149796-10149796 15
44 COSM88292596 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.490C>T p.Q164* 3:10149813-10149813 15
45 COSM88292160 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.551T>C p.L184P 3:10149874-10149874 15
46 COSM88290922 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.345C>G p.H115Q 3:10146518-10146518 15
47 COSM88289274 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 3:10142041-10142041 15
48 COSM88292304 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.269A>T p.N90I 3:10142116-10142116 15
49 COSM88288882 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>A p.S68* 3:10142050-10142050 15
50 COSM88305342 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.492G>T p.Q164H 3:10149815-10149815 15

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma
Sources

Expression for Renal Cell Carcinoma, Nonpapillary

About this section
Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.
Sources

Pathways for Renal Cell Carcinoma, Nonpapillary

About this section

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

36
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.81 VHL TP53 PTEN NRAS MTOR MET
2
PI3K-Akt signaling pathway 36
Show member pathways
 12.92 TP53 PTEN PIK3CA NRAS MTOR MET
3
Endometrial cancer 36
Show member pathways
 12.84 TP53 PTEN PIK3CA NRAS MTOR
4
Pathways in cancer 36
12.76 VHL TP53 PTEN PIK3CA NRAS MTOR
5
Gastric cancer 36
Show member pathways
 12.74 TP53 PTEN PIK3CA NRAS MTOR MET
6
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.68 TP53 PTEN PIK3CA NRAS MTOR MET
7
Development HGF signaling pathway 22
Show member pathways
 12.67 TP53 PTEN PIK3CA NRAS MTOR MET
8
VEGF Signaling 66
Show member pathways
 12.49 TP53 PTEN PIK3CA NRAS MTOR
9
Glioma 36
Show member pathways
 12.46 TP53 PTEN PIK3CA NRAS MTOR MET
10
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.42 PTEN PIK3CA NRAS MTOR
11
Apoptosis Pathway 70
Show member pathways
 12.38 TP53 PIK3CA NRAS MTOR MET ATM
12
Shigellosis 36
12.37 TP53 PIK3CA MTOR ATM
13
Development IGF-1 receptor signaling 22
Show member pathways
 12.37 TP53 PTEN PIK3CA MTOR MET
14
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.33 TP53 PTEN PIK3CA NRAS MTOR MET
15
ErbB signaling pathway 36 1
Show member pathways
 12.31 VHL TP53 PTEN PIK3CA NRAS MTOR
16
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.29 TP53 PTEN PIK3CA MTOR
17
Human T-cell leukemia virus 1 infection 36
12.29 TP53 PTEN PIK3CA NRAS ATM
18
Proteoglycans in cancer 36
12.23 TP53 PIK3CA NRAS MTOR MET
19
mTOR Pathway 70
Show member pathways
 12.17 TP53 PIK3CA NRAS MTOR
20
MAPK Signaling: Mitogens 64
Show member pathways
 12.17 TP53 PTEN PIK3CA NRAS MTOR MET
21
Integrated Breast Cancer Pathway 1
12.14 TP53 PTEN MTOR ATM
22
Longevity regulating pathway 36
Show member pathways
 12.13 TP53 PIK3CA NRAS MTOR
23
Jak Stat Signaling Pathway 66
Show member pathways
 12.08 PIK3CA NRAS MTOR
24
FoxO signaling pathway 36
Show member pathways
 12.08 PTEN PIK3CA NRAS ATM
25
UVA-Induced MAPK Signaling 63
Show member pathways
 12.07 TP53 NRAS MTOR ATM
26
Autophagy - animal 36
12.07 PTEN PIK3CA NRAS MTOR
27
Cellular senescence (KEGG) 36
12.07 TP53 PTEN PIK3CA NRAS MTOR ATM
28
Thyroid hormone signaling pathway 36
12.01 TP53 PIK3CA NRAS MTOR
29
Sphingolipid signaling pathway 36
11.99 TP53 PTEN PIK3CA NRAS
30
Glioblastoma Multiforme 63
11.95 TP53 PTEN NRAS MTOR
31
DNA Damage Response (only ATM dependent) 1
11.92 TP53 PTEN PIK3CA NRAS ATM
32
Type II diabetes mellitus 36 1
Show member pathways
 11.87 PIK3CA MTOR HNF1B HNF1A
33
Small cell lung cancer 36
11.84 TP53 PTEN PIK3CA FHIT
34
TP53 Regulates Metabolic Genes 65
11.8 TP53 PTEN MTOR
35
MicroRNAs in cancer 36
11.77 TP53 PTEN PIK3CA NRAS MTOR MIR200C
36
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.72 RNF139 PIK3CA MTOR
37
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.72 TP53 MTOR ATM
38
Platinum drug resistance 36
11.72 TP53 PIK3CA ATM
39
Pathways Affected in Adenoid Cystic Carcinoma 1
11.59 TP53 SETD2 PTEN PIK3CA ATM
40
Copper homeostasis 1
11.57 TP53 PTEN PIK3CA
41
Integrated Cancer Pathway 1
11.5 TP53 PTEN ATM
42
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics 60
11.4 NRAS MTOR MET
43
Central carbon metabolism in cancer 36
11.28 TP53 PTEN PIK3CA NRAS MTOR MET
44
Extracellular vesicle-mediated signaling in recipient cells 1
11.26 NRAS MTOR MET
45
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.21 PTEN PIK3CA NRAS MTOR
Sources

GO Terms for Renal Cell Carcinoma, Nonpapillary

About this section

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 VHL TP53 PTEN OGG1 HNF1B
2 positive regulation of gene expression GO:0010628 9.83 TP53 PTEN MTOR HNF1B ATM
3 multicellular organism growth GO:0035264 9.67 TP53 MTOR ATM
4 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.63 PTEN MIR200C FLCN
5 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.54 PIK3CA ATM
6 response to glucose GO:0009749 9.54 PTEN HNF1B HNF1A
7 replicative senescence GO:0090399 9.51 TP53 ATM
8 regulation of protein phosphorylation GO:0001932 9.5 PIK3CA MTOR FLCN
9 anoikis GO:0043276 9.48 PIK3CA MTOR
10 negative regulation of protein kinase B signaling GO:0051898 9.43 PTEN MIR200C FLCN
11 negative regulation of cell size GO:0045792 9.4 PTEN MTOR
12 pancreas development GO:0031016 9.33 MET HNF1B HNF1A
13 regulation of pronephros size GO:0035565 8.96 HNF1B HNF1A
14 liver development GO:0001889 8.92 PIK3CA MET HNF1B HNF1A

Molecular functions related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.35 NRAS MTOR HNF1B FLCN ATM
2 identical protein binding GO:0042802 9.23 TP53 PTEN MTOR MET HNF1B HNF1A
3 1-phosphatidylinositol-3-kinase activity GO:0016303 9.16 PIK3CA ATM
Sources

Sources for Renal Cell Carcinoma, Nonpapillary

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....